Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study

NCT02628028 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02628028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02628028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Terminated
Start date
August 22, 2016
Completion date
August 15, 2018
Enrollment
286 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis